News | June 08, 2009

Study Finds 3D Echo is a Stronger Outcome Predictor Than 2D

June 9, 2009 – Physicians can better predict potentially life-threatening cardiac events with real-time, three-dimensional echocardiography technology, according to a study released at the 20th Annual Scientific Sessions of the American Society of Echocardiography (ASE) in Washington, D.C.

The study concluded that 3D measurements could help guide management decisions on how to best treat the patient and better predict the patient’s chance of survival.

Left ventricular end systolic volume measured by 2D echocardiography is an important correlate of survival. Researchers sought to determine whether 3D echo was more predictive of outcome than 2D echo. The study included 535 patients referred for left ventricle assessment. Patients were assessed with 2D and 3D echocardiography.

Over four to five years, cardiac admission, incident heart failure, atrial fibrillation and all-cause mortality information was obtained in 461 of 504 patients with images suitable for measurement. The results showed 48 cardiac events (10 percent) including 34 deaths. Larger left ventricular end-systolic volume and lower ejection fraction were associated with worse outcome.

The addition of 2D echo end-systolic volume increased the association of clinical variables—renal disease, left ventricular impairment and age – with outcome, but 3D echo end-systolic volume increased the strength of association. Similarly, the incremental value of 2D echo ejection fraction was exceeded by 3D echo ejection fraction.

The study was conducted by Carly Jenkins, Tony Stanton and Thomas H. Marwick at University of Queensland in Woolloongabba, Australia.

For more information: www.asecho.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now